Aliases & Classifications for Arteriosclerosis

MalaCards integrated aliases for Arteriosclerosis:

Name: Arteriosclerosis 12 54 6 44 15 17 70
Arteriosclerotic Vascular Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2349
MeSH 44 D001161
NCIt 50 C34398
SNOMED-CT 67 195251000
ICD10 32 I70
UMLS 70 C0003850

Summaries for Arteriosclerosis

Disease Ontology : 12 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries.

MalaCards based summary : Arteriosclerosis, also known as arteriosclerotic vascular disease, is related to arteriosclerosis obliterans and coronary heart disease 1, and has symptoms including angina pectoris An important gene associated with Arteriosclerosis is HS3ST1 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Degradation of the extracellular matrix. The drugs Atorvastatin and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include endothelial, kidney and smooth muscle, and related phenotypes are cardiovascular system and cellular

Wikipedia : 73 Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. This... more...

Related Diseases for Arteriosclerosis

Diseases in the Arteriosclerosis family:

Arteriosclerosis, Severe Juvenile

Diseases related to Arteriosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 507)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 33.2 VCAM1 MIR21 ICAM1 HGF ADIPOQ
2 coronary heart disease 1 32.2 SERPINE1 PON1 HMGCR APOB APOA1 ADIPOQ
3 hyperlipoproteinemia, type iii 32.1 HMGCR APOB APOA1
4 atherosclerosis susceptibility 32.0 VCAM1 SERPINE1 PPARG PON1 MGP ICAM1
5 lipoprotein quantitative trait locus 31.9 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
6 angina pectoris 31.4 ICAM1 EDN1 APOA1 ADIPOQ
7 peripheral vascular disease 31.3 VCAM1 SERPINE1 HMGCR CCL2 APOB APOA1
8 hypertriglyceridemia, familial 31.3 SERPINE1 APOB APOA1
9 buerger disease 31.2 VCAM1 PON1 ICAM1 EDN1
10 lipid metabolism disorder 31.1 SERPINE1 PPARG PON1 MIR126 HMGCR CCL2
11 cerebrovascular disease 31.1 VCAM1 SPP1 SERPINE1 PON1 MIR21 ICAM1
12 homocysteinemia 31.1 VCAM1 SERPINE1 PON1 ELN CCL2
13 limb ischemia 31.1 SERPINE1 MIR21 ICAM1 HGF EDN1 CCL2
14 end stage renal disease 31.0 SPP1 PON1 MGP ICAM1 CCL2 APOB
15 coronary stenosis 30.9 SERPINE1 PON1 MIR21 ICAM1 APOB APOA1
16 fatty liver disease 30.9 SERPINE1 PPARG APOB ADIPOQ
17 carotid stenosis 30.9 VCAM1 SPP1 ICAM1 ADIPOQ
18 hyperglycemia 30.9 VCAM1 SERPINE1 PPARG APOB ADIPOQ
19 pulmonary hypertension 30.9 SERPINE1 MIR21 HMOX1 EDN1 CCL2
20 ischemia 30.9 PON1 MIR21 ICAM1 HMOX1 HGF EDN1
21 vascular disease 30.9 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
22 familial hypercholesterolemia 30.8 VCAM1 SERPINE1 PON1 HMGCR APOB APOA1
23 takayasu arteritis 30.8 VCAM1 ICAM1 EDN1
24 arteries, anomalies of 30.8 VCAM1 SERPINE1 MIR21 MIR126 ICAM1 EDN1
25 hyperinsulinism 30.8 SERPINE1 PPARG EDN1 APOB ADIPOQ
26 aortic aneurysm, familial abdominal, 1 30.7 VCAM1 SPP1 SERPINE1 MIR126 ICAM1 ELN
27 peripheral artery disease 30.7 VCAM1 ICAM1 HMOX1 HGF EDN1 CCL2
28 intermediate coronary syndrome 30.7 VCAM1 MIR126 APOB APOA1
29 uremia 30.7 SPP1 PON1 MGP
30 hypertension, essential 30.6 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
31 glomerulonephritis 30.6 VCAM1 SPP1 ICAM1 CCL2
32 proteasome-associated autoinflammatory syndrome 1 30.6 VCAM1 PPARG ICAM1 CCL2 ADIPOQ
33 cerebral aneurysms 30.6 HMOX1 ELN
34 systemic lupus erythematosus 30.6 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
35 carotid artery disease 30.6 PON1 MIR126 CCL2 APOB APOA1
36 non-alcoholic fatty liver disease 30.6 SPP1 SERPINE1 PPARG MIR21 MIR126 HMOX1
37 aortic atherosclerosis 30.5 SPP1 PON1 APOB ADIPOQ
38 connective tissue disease 30.5 SPP1 MIR21 MIR126 ELN EDN1 CCL2
39 kidney disease 30.5 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
40 non-alcoholic steatohepatitis 30.4 SERPINE1 PPARG MIR21 HGF CCL2 ADIPOQ
41 iga glomerulonephritis 30.4 SPP1 ICAM1 CCL2
42 hyperlipidemia, familial combined, 3 30.4 PON1 HMGCR APOB APOA1 ADIPOQ
43 chronic kidney disease 30.4 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
44 retinal vascular disease 30.4 MIR21 MIR126 ICAM1 CCL2
45 osteoporosis 30.4 SPP1 SERPINE1 PPARG MIR21 MGP ICAM1
46 type 2 diabetes mellitus 30.3 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR126
47 diabetes mellitus 30.3 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR126
48 body mass index quantitative trait locus 11 30.3 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
49 apnea, obstructive sleep 30.3 SERPINE1 ICAM1 EDN1 ADIPOQ
50 venous insufficiency 30.3 VCAM1 SERPINE1 ICAM1 ELN

Graphical network of the top 20 diseases related to Arteriosclerosis:



Diseases related to Arteriosclerosis

Symptoms & Phenotypes for Arteriosclerosis

UMLS symptoms related to Arteriosclerosis:


angina pectoris

MGI Mouse Phenotypes related to Arteriosclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ADIPOQ APOA1 APOB EDN1 HGF HMOX1
2 cellular MP:0005384 10.13 ADIPOQ APOA1 APOB DAB2IP HGF HMGCR
3 growth/size/body region MP:0005378 10.07 ADIPOQ APOB EDN1 HGF HMGCR HMOX1
4 homeostasis/metabolism MP:0005376 10.03 ADIPOQ APOA1 APOB DAB2IP EDN1 HMGCR
5 liver/biliary system MP:0005370 9.61 ADIPOQ APOA1 APOB HGF HMGCR HMOX1
6 muscle MP:0005369 9.23 ADIPOQ APOB EDN1 HMOX1 ICAM1 MGP

Drugs & Therapeutics for Arteriosclerosis

Drugs for Arteriosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
3
Polyestradiol phosphate Approved Phase 4 28014-46-2
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
9
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
10
Atenolol Approved Phase 4 29122-68-7 2249
11
Propranolol Approved, Investigational Phase 4 525-66-6 4946
12
Remifentanil Approved Phase 4 132875-61-7 60815
13
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Dipyridamole Approved Phase 4 58-32-2 3108
17
Pravastatin Approved Phase 4 81093-37-0 54687
18
Insulin aspart Approved Phase 4 116094-23-6 16132418
19
Insulin detemir Approved Phase 4 169148-63-4 5311023
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
22
Ezetimibe Approved Phase 4 163222-33-1 150311
23
Sevelamer Approved Phase 4 52757-95-6
24
Calcium acetate Approved, Investigational Phase 4 62-54-4
25
Probucol Approved, Investigational Phase 4 23288-49-5 4912
26
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
27
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
28
tannic acid Approved Phase 4 1401-55-4
29
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
30
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
31
Evolocumab Approved Phase 4 1256937-27-5
32
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
33
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
34
Mycophenolic acid Approved Phase 4 24280-93-1 446541
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
37
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
38
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
39
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
40 Beraprost Investigational Phase 4 88430-50-6
41 Prasugrel hydrochloride Phase 4 389574-19-0
42 Estrogens Phase 4
43 Hormone Antagonists Phase 4
44 Estrogens, Conjugated (USP) Phase 4
45 Progestins Phase 4
46 Contraceptive Agents Phase 4
47 Estradiol 3-benzoate Phase 4
48 Estradiol 17 beta-cypionate Phase 4
49 Cyclooxygenase 2 Inhibitors Phase 4
50 calcium heparin Phase 4

Interventional clinical trials:

(show top 50) (show all 315)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
3 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
4 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
5 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
6 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
7 A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease Completed NCT00471341 Phase 4 Celecoxib;placebo
8 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
9 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
10 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
11 Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts. Completed NCT00611910 Phase 4
12 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
13 Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Completed NCT02510547 Phase 4
14 Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study Completed NCT01374698 Phase 4 Aspirin
15 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
16 A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis Completed NCT00163202 Phase 4 Atorvastatin
17 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
18 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
19 A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Completed NCT00380939 Phase 4 Atorvastatin;Pravastatin
20 A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus Completed NCT00368953 Phase 4
21 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
22 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
23 Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial Completed NCT00292721 Phase 4 Celecoxib
24 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
25 The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial Completed NCT00657943 Phase 4 metformin;insulin detemir;insulin aspart + insulin aspart protamin;Insulin aspart
26 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
27 Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI Completed NCT00390585 Phase 4 Iodixanol 320;Iomeprol 350
28 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
29 A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population. Completed NCT00319449 Phase 4 Ezetimibe;Placebo;Atorvastatin 10 mg
30 Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism Completed NCT00274144 Phase 4 telmisartan 40 mg;placebo 40 mg
31 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
32 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
33 Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE) Completed NCT00351676 Phase 4 Optimizing therapeutic treatments
34 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
35 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
36 Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis Completed NCT03485495 Phase 4 Divaza;Placebo
37 Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial Recruiting NCT04624854 Phase 4 Clopidogrel and Aspirin dual-antiplatelet therapy;Aspirin monotherapy
38 Effects of Melatonin on Progression of Coronary Artery Calcification Recruiting NCT03966235 Phase 4 Melatonin 3 mg;Placebo
39 The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging Recruiting NCT03753555 Phase 4 Atorvastatin Calcium;Atorvastatin Calcium;Probucol
40 Reducing Intracranial atheroSclErosis With Repatha Not yet recruiting NCT04573777 Phase 4 Repatha
41 Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients Terminated NCT02786979 Phase 4 Beraprost;Aspirin
42 Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients. Terminated NCT01276834 Phase 4 everolimus
43 Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions Terminated NCT02601664 Phase 4
44 EARly Prevention of aTHeroma Progression Terminated NCT02105623 Phase 4 Rosuvastatin
45 A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients) Terminated NCT00274105 Phase 4 telmisartan;Placebo
46 Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis Terminated NCT01104311 Phase 4
47 Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis: a Study Based on Whole-brain CTP Withdrawn NCT04325932 Phase 4 Urinary Kallikrein
48 The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries Withdrawn NCT02423265 Phase 4 Ranolazine;Placebo
49 Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry Withdrawn NCT02974777 Phase 4 DAPT reduction;DAPT on-target;DAPT intensification
50 Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)? Unknown status NCT01723345 Phase 3 omega 3

Search NIH Clinical Center for Arteriosclerosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: arteriosclerosis

Genetic Tests for Arteriosclerosis

Anatomical Context for Arteriosclerosis

MalaCards organs/tissues related to Arteriosclerosis:

40
Endothelial, Kidney, Smooth Muscle, Heart, Bone, Skin, Eye

Publications for Arteriosclerosis

Articles related to Arteriosclerosis:

(show top 50) (show all 11936)
# Title Authors PMID Year
1
HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. 6
28126521 2017
2
Assessing the function of genetic variants in candidate gene association studies. 6
15266341 2004
3
Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. 61 54
20097344 2010
4
Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. 54 61
20150911 2010
5
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 61 54
20078196 2010
6
Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. 54 61
19066833 2009
7
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. 61 54
19132220 2008
8
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. 54 61
18464944 2008
9
Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. 54 61
18332637 2008
10
Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. 54 61
18670142 2008
11
[Endothelin-1 production and its involvement in cardiovascular diseases]. 61 54
17827914 2007
12
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]. 54 61
17489075 2007
13
General anesthesia and methylenetetrahydrofolate reductase deficiency. 61 54
18008117 2007
14
[Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells]. 61 54
17274908 2006
15
Endothelial-mediated regulation of cerebral microcirculation. 61 54
17244945 2006
16
Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. 54 61
16844909 2006
17
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 61 54
16616959 2006
18
TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. 61 54
16796604 2006
19
Protective genes in the vessel wall: Modulators of graft survival and function. 54 61
16829794 2006
20
Signaling and functions of angiopoietin-1 in vascular protection. 54 61
16645151 2006
21
Recent advances in the relationship between obesity, inflammation, and insulin resistance. 54 61
16613757 2006
22
[Effects of active components extracted from Qixue Bingzhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor genes]. 54 61
16409966 2006
23
Adrenomedullin: a protective factor for blood vessels. 61 54
16141406 2005
24
Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. 54 61
15744522 2005
25
Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. 54 61
15882555 2005
26
Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. 54 61
15578196 2005
27
Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. 54 61
15550473 2005
28
[Endothelin-1 and arteriosclerosis]. 61 54
15506470 2004
29
Eukaryotic expression vector of heme oxygenase-1 and its expression in endothelial cell. 54 61
15313669 2004
30
CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. 54 61
15257175 2004
31
Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. 61 54
15181084 2004
32
Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. 54 61
15072997 2004
33
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. 61 54
15225502 2004
34
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 54 61
14963043 2004
35
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. 61 54
14691581 2004
36
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. 54 61
12942166 2003
37
[Neurological aspects in antiphospholipid syndrome]. 54 61
15152454 2003
38
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 54 61
14581407 2003
39
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. 61 54
14583180 2003
40
[Regulatory effect of yishou tiaozhi tablet on lipids in patients with primary hyperlipidemia]. 61 54
12764909 2003
41
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 61 54
12628953 2003
42
The concentration of lipids, lipoproteins and apolipoproteins in cord blood serum of newborns in the course of intrauterine period. 54 61
15323161 2003
43
Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. 54 61
12791519 2003
44
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. 61 54
12411463 2002
45
Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. 54 61
12231371 2002
46
Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. 61 54
12452315 2002
47
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. 54 61
12616975 2002
48
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. 61 54
12560586 2002
49
A survey of the dietary nutritional composition of centenarians. 54 61
11677774 2001
50
[Effect of lower androgen levels on arteriosclerosis]. 61 54
11769606 2001

Variations for Arteriosclerosis

ClinVar genetic disease variations for Arteriosclerosis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HS3ST1 NM_005114.3(HS3ST1):c.-108-6848A>G SNV risk factor 441163 rs16881446 GRCh37: 4:11408585-11408585
GRCh38: 4:11406961-11406961

Expression for Arteriosclerosis

Search GEO for disease gene expression data for Arteriosclerosis.

Pathways for Arteriosclerosis

Pathways related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.03 VCAM1 SPP1 SERPINE1 PPARG ICAM1 CCL2
2
Show member pathways
12.59 VCAM1 SPP1 SERPINE1 ICAM1 ELN
3
Show member pathways
12.19 SERPINE1 ICAM1 CCL2 APOB APOA1
4 11.86 VCAM1 ICAM1 HMOX1 EDN1 CCL2
5 11.76 VCAM1 SPP1 PPARG ADIPOQ
6 11.71 VCAM1 ICAM1 HMOX1 HGF CCL2
7 11.68 HMOX1 HGF CCL2
8 11.6 PPARG APOA1 ADIPOQ
9 11.6 VCAM1 ICAM1 EDN1 DAB2IP CCL2
10 11.51 SERPINE1 HMOX1 EDN1
11 11.37 VCAM1 ICAM1 HGF CCL2
12 11.35 VCAM1 SERPINE1 ICAM1 EDN1 CCL2
13 11.25 VCAM1 ICAM1 APOA1
14 11.2 MGP HMOX1 CCL2
15 10.9 SPP1 HMOX1 HGF ELN EDN1 CCL2
16 10.78 VCAM1 ICAM1 CCL2

GO Terms for Arteriosclerosis

Cellular components related to Arteriosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.02 VCAM1 SPP1 SERPINE1 PON1 MIR21 MGP
2 extracellular region GO:0005576 9.9 SPP1 SERPINE1 PON1 MGP HGF ELN
3 extracellular space GO:0005615 9.47 VCAM1 SPP1 SERPINE1 PON1 MIR21 MIR126
4 low-density lipoprotein particle GO:0034362 9.46 APOB APOA1
5 chylomicron GO:0042627 9.43 APOB APOA1
6 high-density lipoprotein particle GO:0034364 9.43 PON1 APOB APOA1
7 collagen-containing extracellular matrix GO:0062023 9.43 SERPINE1 MGP ICAM1 ELN APOA1 ADIPOQ
8 spherical high-density lipoprotein particle GO:0034366 9.4 PON1 APOA1
9 intermediate-density lipoprotein particle GO:0034363 9.32 APOB APOA1

Biological processes related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.99 SERPINE1 HMOX1 DAB2IP CCL2
2 cytokine-mediated signaling pathway GO:0019221 9.99 VCAM1 ICAM1 HMOX1 HGF CCL2
3 response to lipopolysaccharide GO:0032496 9.95 VCAM1 ICAM1 EDN1 APOB
4 extracellular matrix organization GO:0030198 9.95 VCAM1 SPP1 SERPINE1 ICAM1 ELN
5 negative regulation of cell migration GO:0030336 9.93 SERPINE1 MIR21 MIR126 ADIPOQ
6 cellular response to hypoxia GO:0071456 9.9 MIR126 ICAM1 HMOX1 EDN1
7 cholesterol homeostasis GO:0042632 9.89 HMGCR APOB APOA1
8 cellular response to interferon-gamma GO:0071346 9.89 ICAM1 EDN1 CCL2
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 MIR21 MIR126 ICAM1 HMGCR CCL2
10 positive regulation of inflammatory response GO:0050729 9.88 SERPINE1 MIR21 MIR126
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 ICAM1 HGF ADIPOQ
12 regulation of lipid metabolic process GO:0019216 9.88 PPARG HMGCR APOA1
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 MIR21 MIR126 HGF
14 response to organic substance GO:0010033 9.87 SPP1 PPARG APOB
15 cell chemotaxis GO:0060326 9.87 VCAM1 HGF CCL2
16 response to ethanol GO:0045471 9.87 VCAM1 ICAM1 HMGCR ADIPOQ
17 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.86 MIR21 DAB2IP ADIPOQ
18 response to nutrient levels GO:0031667 9.85 PON1 HMGCR ADIPOQ
19 regulation of blood pressure GO:0008217 9.84 PPARG HMOX1 EDN1
20 cholesterol metabolic process GO:0008203 9.84 PON1 HMGCR APOB APOA1
21 response to estrogen GO:0043627 9.83 PPARG HMOX1 APOA1
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 HMOX1 HMGCR EDN1
23 response to hypoxia GO:0001666 9.83 VCAM1 ICAM1 HMOX1 EDN1 ADIPOQ
24 animal organ regeneration GO:0031100 9.81 PPARG HGF APOA1
25 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.8 PPARG HMOX1 ADIPOQ
26 cellular response to lipopolysaccharide GO:0071222 9.8 SERPINE1 MIR21 ICAM1 DAB2IP CCL2
27 response to drug GO:0042493 9.8 PPARG ICAM1 HMOX1 EDN1 APOA1 ADIPOQ
28 negative regulation of MAP kinase activity GO:0043407 9.79 HMGCR DAB2IP ADIPOQ
29 negative regulation of endothelial cell apoptotic process GO:2000352 9.78 SERPINE1 MIR126 ICAM1
30 positive regulation of angiogenesis GO:0045766 9.77 SERPINE1 MIR21 MIR126 HMOX1 HGF
31 cellular response to interleukin-1 GO:0071347 9.76 ICAM1 EDN1 DAB2IP CCL2
32 response to nicotine GO:0035094 9.75 VCAM1 HMOX1 EDN1
33 negative regulation of vascular endothelial cell proliferation GO:1905563 9.73 PPARG MIR126 CCL2
34 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.72 MIR21 ICAM1
35 lipoprotein transport GO:0042953 9.72 PPARG APOB
36 negative regulation of blood coagulation GO:0030195 9.71 SERPINE1 EDN1
37 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.7 PPARG ADIPOQ
38 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.7 MIR21 MIR126 HMOX1
39 chylomicron assembly GO:0034378 9.69 APOB APOA1
40 low-density lipoprotein particle clearance GO:0034383 9.69 HMOX1 APOB ADIPOQ
41 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 APOA1 ADIPOQ
42 negative regulation of hormone secretion GO:0046888 9.68 EDN1 ADIPOQ
43 regulation of p38MAPK cascade GO:1900744 9.67 HGF DAB2IP
44 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.67 MIR21 EDN1
45 chylomicron remodeling GO:0034371 9.67 APOB APOA1
46 positive regulation of fatty acid metabolic process GO:0045923 9.65 PPARG ADIPOQ
47 positive regulation of cholesterol efflux GO:0010875 9.65 PON1 APOA1 ADIPOQ
48 negative regulation of inflammatory response GO:0050728 9.65 PPARG MIR126 HGF APOA1 ADIPOQ
49 lipoprotein biosynthetic process GO:0042158 9.64 APOB APOA1
50 membrane to membrane docking GO:0022614 9.64 VCAM1 ICAM1

Molecular functions related to Arteriosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 SPP1 EDN1 CCL2 ADIPOQ
2 signaling receptor binding GO:0005102 9.02 SERPINE1 EDN1 CCL2 APOA1 ADIPOQ

Sources for Arteriosclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....